



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Peled et al.
SERIAL NUMBER: 10/774,843 EXAMINER : Maria Gomez Leavitt
FILING DATE: February 9, 2004 ART UNIT : 1633
FOR: EXPANSION OF RENEWABLE STEM CELL POPULATIONS

Mail Stop Amendment

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450



TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

1. Supplemental Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (1 page), in duplicate;
3. Copies of Cited References: C284-C288; and
4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 24024-505 CON. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

Matthew Parnis 50,572

Ivor R. Elrifi, Reg. No. 39,529
Attorney(s) for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.

Address all written correspondence to

Customer no.: 30623


Tel: (617) 542-6000

Fax: (617) 542-2241

Date: February 14, 2007

Express Mail Label No.: EV 978772038 US
Date of Deposit: February 14, 2007

Attorney Docket No.: 24024-505 CON



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Peled et al.
SERIAL NUMBER: 10/774,843 EXAMINER : Maria Gomez Leavitt
FILING DATE: February 9, 2004 ART UNIT : 1633
FOR: EXPANSION OF RENEWABLE STEM CELL POPULATIONS

MAIL STOP AMENDMENT

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Supplemental Information Disclosure Statement is being filed within three months of the mailing date of the Supplementary European Search Report for EP 03 70 6871, mailed January 15, 2007. Accordingly, no fee or certification is believed required.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANT: Peled et al.
U.S.S.N.: 10/774,843

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 24024-505 CON.

Respectfully submitted,

 Matthew Parn 50,572

Ivor R. Elrifi, Reg. No. 39,529

Attorney(s) for Applicants

MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.

Address all written correspondence to

Customer no.: 30623

Tel: (617) 542-6000

Fax: (617) 542-2241

Date: February 14, 2007

TRA 2255308v.1

Express Mail No.: EV 978772038 US
Date of Deposit: February 14, 2007



Page 1 of 1
Attorney Docket No.: 24024-505 CON

Please type a plus sign (+) in this box



PTO/SB (12-97)
Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number		10/774,843	
				Filing Date		February 9, 2004	
				First Named Inventor		Peled	
				Group Art Unit		1633	
				Examiner Name		Maria Gomez Leavitt	
				Attorney Docket Number		24024-505 CON	
U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
U.S. PUBLISHED APPLICATION DOCUMENTS							
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No		
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					
	C284	Kumagai et al., "Ligation of CD38 suppresses human B lymphopoiesis", <i>J. Exp. Med.</i> , 181(3):1101-1110 (1995)					
	C285	Ramsfjell et al., "Distinct requirements for optimal growth and in vitro expansion of human CD34 ⁺ CD38 ⁺ bone marrow long-term culture-initiating cells (LTC-IC), extended LTC-IC, and murine in vivo long-term reconstituting stem cells", <i>Blood</i> , 94(12):4093-4102 (1999)					
	C286	Silvennoinen et al., "CD38 Signal transduction in human B cell precursors", <i>J. Immunol.</i> , 156(1):100-107 (1996)					
	C287	Todisco et al., "CD38 ligation inhibits normal and leukemic myelopoiesis", <i>Blood</i> , 95(2):535-542 (2000)					
	C288	Supplementary European Search Report for EP 03 70 6871, mailed January 15, 2007.					

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.